DNA damage response inhibitors in cholangiocarcinoma: current progress and perspectives

Basit Öğe Kaydı
dc.authoridÖykü Gönül Geyik / 0000-0003-3014-1253en_US
dc.authoridEngin Ulukaya / 0000-0003-4875-5472en_US
dc.authorscopusidÖykü Gönül Geyik / 56695248800
dc.authorscopusidEngin Ulukaya / 6602927353
dc.authorwosidÖykü Gönül Geyik / AAL-3308-2020en_US
dc.authorwosidEngin Ulukaya / K-5792-2018en_US
dc.contributor.authorAnichini, Giulia
dc.contributor.authorUlukaya, Engin
dc.contributor.authorMarra, Fabio
dc.contributor.authorRaggi, Chiara
dc.contributor.authorGeyik, Öykü Gönül
dc.date.accessioned2022-05-20T07:09:27Z
dc.date.available2022-05-20T07:09:27Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümüen_US
dc.description.abstractCholangiocarcinoma (CCA) is a poorly treatable type of cancer and its incidence is dramatically increasing. The lack of understanding of the biology of this tumor has slowed down the identification of novel targets and the development of effective treatments. Based on next generation sequencing profiling, alterations in DNA damage response (DDR)-related genes are paving the way for DDR-targeting strategies in CCA. Based on the notion of synthetic lethality, several DDR-inhibitors (DDRi) have been developed with the aim of accumulating enough DNA damage to induce cell death in tumor cells. Observing that DDRi alone could be insufficient for clinical use in CCA patients, the combination of DNA-damaging regimens with targeted approaches has started to be considered, as evidenced by many emerging clinical trials. Hence, novel therapeutic strategies combining DDRi with patient-specific targeted drugs could be the next level for treating cholangiocarcinoma.en_US
dc.identifier.citationGönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells. 2022 Apr 26;11(9):1463. doi: 10.3390/cells11091463. PMID: 35563769; PMCID: PMC9101358.en_US
dc.identifier.doi10.3390/cells11091463en_US
dc.identifier.issn2073-4409en_US
dc.identifier.issue9en_US
dc.identifier.pmid35563769en_US
dc.identifier.scopus2-s2.0-85129086206en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.3390/cells11091463
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2673
dc.identifier.volume11en_US
dc.identifier.wosWOS:000794639800001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGönül Geyik, Öykü
dc.institutionauthorUlukaya, Engin
dc.language.isoenen_US
dc.publisherPubMeden_US
dc.relation.ispartofCellsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiliary Tract Canceren_US
dc.subjectTargeted Therapyen_US
dc.subjectDNA Damageen_US
dc.subjectSynthetic Lethalityen_US
dc.subjectPARPen_US
dc.subjectWee1en_US
dc.titleDNA damage response inhibitors in cholangiocarcinoma: current progress and perspectivesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 2 / 2
Küçük Resim
İsim:
cells-11-01463 (1).pdf
Boyut:
932.94 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Küçük Resim
İsim:
cells-11-01463 (1).pdf
Boyut:
932.94 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Beslenme ve Diyetetik Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu